Published in Ann Oncol on March 15, 2011
Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. Anticancer Agents Med Chem (2012) 0.94
A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. Oncotarget (2013) 0.87
Efficacy and tolerability of lapatinib in the management of breast cancer. Breast Cancer (Auckl) (2012) 0.83
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.79
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res (2016) 0.75
Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open (2017) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science (1991) 12.93
The EGF receptor family as targets for cancer therapy. Oncogene (2000) 5.44
Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. Science (1990) 4.21
Src homology region 2 domains direct protein-protein interactions in signal transduction. Proc Natl Acad Sci U S A (1990) 4.13
Binding of GAP to activated PDGF receptors. Science (1990) 3.89
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res (2001) 3.62
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol (2011) 3.55
Attitudes and barriers to incident reporting: a collaborative hospital study. Qual Saf Health Care (2006) 3.23
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol (2010) 3.00
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene (2008) 2.72
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol (2003) 2.63
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein. Mol Cell Biol (1991) 2.40
rho family GTPase activating proteins p190, bcr and rhoGAP show distinct specificities in vitro and in vivo. EMBO J (1993) 2.31
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol (2013) 2.06
Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res (1993) 2.03
SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Mol Cell Biol (1992) 2.00
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol (2007) 1.96
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol (2009) 1.89
Surgeons and cognitive processes. Br J Surg (2003) 1.85
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol (2004) 1.85
Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes Relat Metab Disord (2003) 1.85
Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr (2001) 1.84
Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature (1999) 1.68
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol (1998) 1.68
Heat shock protein Hsp60-reactive gamma delta cells: a large, diversified T-lymphocyte subset with highly focused specificity. Proc Natl Acad Sci U S A (1992) 1.66
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol (2008) 1.66
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol (2008) 1.66
A comparison of biochemical and functional alterations of rat and human erythrocytes stored in CPDA-1 for 29 days: implications for animal models of transfusion. Transfus Med (2000) 1.66
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol (2010) 1.63
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res (1999) 1.59
Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J (1991) 1.58
Reverse transcriptase from avian myeloblastosis virus. J Virol (1979) 1.55
Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. J Biol Chem (2001) 1.54
Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res (1999) 1.54
Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol (1998) 1.52
Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest (2002) 1.50
Diverticular disease of the colon--on the rise: a study of hospital admissions in England between 1989/1990 and 1999/2000. Aliment Pharmacol Ther (2003) 1.49
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene (2009) 1.48
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol (2010) 1.48
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol (1999) 1.47
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol (2001) 1.46
Preliminary criteria for the definition of allergic rhinitis: a systematic evaluation of clinical parameters in a disease cohort (II) Clin Exp Allergy (2000) 1.46
New staging system of the fifth Joint National Committee report on the detection, evaluation, and treatment of high blood pressure (JNC-V) alters assessment of the severity and treatment of hypertension. Hypertension (1996) 1.44
Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev (2000) 1.44
Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest (1997) 1.43
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol (2012) 1.40
Emerging targeted therapies in triple-negative breast cancer. Ann Oncol (2012) 1.40
Which three-year-olds attend preschool facilities? Child Care Health Dev (1976) 1.39
Reproducibility of measurements of trace gas concentrations in expired air. Gastroenterology (1991) 1.39
A role for a PDZ protein in the early secretory pathway for the targeting of proTGF-alpha to the cell surface. Mol Cell (1999) 1.39
Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer (1997) 1.39
Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol (2009) 1.37
Methanogens outcompete sulphate reducing bacteria for H2 in the human colon. Gut (1994) 1.32
Platelet-derived growth factor increases the in vivo activity of phospholipase C-gamma 1 and phospholipase C-gamma 2. Mol Cell Biol (1991) 1.30
Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res (2002) 1.24
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res (1997) 1.23
Phospholipase C isozymes: structural and functional similarities. Ciba Found Symp (1990) 1.21
Acute and chronic pancreatitis--diseases on the rise: a study of hospital admissions in England 1989/90-1999/2000. Aliment Pharmacol Ther (2002) 1.20
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat (2009) 1.19
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol (1994) 1.18
Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol (2007) 1.18
Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer (2008) 1.16
Discussing complementary therapies with cancer patients: what should we be talking about? J Clin Oncol (2000) 1.16
Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol (2002) 1.16
Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci U S A (1996) 1.16
Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology (2002) 1.14
Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch Surg (1999) 1.12
First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol (2013) 1.12
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol (2011) 1.10
Molecular study of the T cell repertoire in family contacts and patients with leprosy. J Immunol (1989) 1.10
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol (2011) 1.09
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol (2013) 1.08
Detection of intrauterine growth retardation by ultrasound: preliminary communication. J R Soc Med (1981) 1.08
Gallstones--an increasing problem: a study of hospital admissions in England between 1989/1990 and 1999/2000. Aliment Pharmacol Ther (2003) 1.06
A rapid and simple assay to determine if macroamylase is the cause of hyperamylasemia. Gastroenterology (1982) 1.06
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol (2010) 1.05
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer (2008) 1.04
Pharmacists' preferences for continuing education and certificate programs. Ann Pharmacother (2001) 1.04
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer (2011) 1.04
Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. NeuroRehabilitation (2009) 1.03
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and management. J Clin Apher (1998) 1.03
The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP). J Cell Sci (1999) 1.02
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer (2008) 1.02
Isoelectric focusing studies of human serum and tissue isoamylases. J Lab Clin Med (1977) 1.02
Analysis of middle tumor antigen and pp60c-src interactions in polyomavirus-transformed rat cells. J Virol (1987) 1.02
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat (2010) 1.02
Protein kinase from avian myeloblastosis virus. J Virol (1978) 1.02
Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun (1992) 1.01
Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst (2001) 1.01
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol (2011) 1.01
Effects of substitution of threonine 654 of the epidermal growth factor receptor on epidermal growth factor-mediated activation of phospholipase C. J Biol Chem (1990) 1.01